Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.

CAS：80125-14-0
中文别名：(S)-3-溴-N-[(1-乙基-2-吡咯烷基)甲基]-2,6-二甲氧基苯甲酰胺;
英文别名：remoxipride;Roxiam;(S)-3-bromo-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide;Remoxipride [USAN:BAN:INN];Remoxiprida;(-)-N-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine;Remoxiprida [INN-Spanish];FLA-731;remoxipiride;S(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxy-benzamide;(S)-remoxipride;Romoxipride;Remoxipridum;Remoxipridum [INN-Latin];
分子式：C16H23BrN2O3
分子量：371.269
精确质量：370.089
Psa：50.8
Logp：3.0092

密度：1.292
沸点：439.9ºC at 760 mmHg
闪点：219.8ºC
折射率：1.54

安全说明：S26; S36; S24/25
危险类别码：R36/37/38
WGK Germany：3
危险品标志：Xi

生产方法
2,6-二甲氧基苯甲酸先溴化,得到3-溴2,6-二甲氧基苯甲酸。然后用二氯亚砜氯化为相应的苯甲酰氯,再和2-氨甲基1-乙基吡咯烷反应,得瑞莫必利。 抗精神病药,对多巴胺受体的亚型赐有高度的选择性,可阻断多巴胺与D2受体的结合,但对非多巴胺的神经介质如5-羟色胺、去甲肾上腺素、乙酰胆碱、组胺、GABA的受体的亲和性很低或没有,因而减少了许多副作用。用于急、慢性精神分裂症和以妄想、幻觉和思维紊乱为主要症状的其它精神病的治疗。
用途
抗精神病药,对多巴胺受体的亚型赐有高度的选择性,可阻断多巴胺与D2受体的结合,但对非多巴胺的神经介质如5-羟色胺、去甲肾上腺素、乙酰胆碱、组胺、GABA的受体的亲和性很低或没有,因而减少了许多副作用。用于急、慢性精神分裂症和以妄想、幻觉和思维紊乱为主要症状的其它精神病的治疗。